Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 47Carcinoma, Non-Small-Cell Lung 14Neoplasm Metastasis 11Neoplasms 9Colorectal Neoplasms 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Lung Neoplasms 6Sarcoma 5Melanoma 4Esophageal Neoplasms 3Cholangiocarcinoma 3Brain Neoplasms 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Pancreatic Diseases 2Gastrointestinal Neoplasms 2Carcinoma 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Tongue Neoplasms 1TNBC 1Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1

Interventions

Gemcitabine 3ensituximab 1Lead 1Immunotherapy, Adoptive 1Cetuximab 1Bevacizumab 1Atu027 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Pancreatic Ductal × 130-nm albumin-bound paclitaxel × Clear all
NCT06445062 2026-04-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Revolution Medicines, Inc.

Phase 1/2 Recruiting
1,130 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡